January 18-22, 2016 | Town and Country Resort Hotel | SAN DIEGO, CA 
January 18-22, 2016 | Town and Country Resort Hotel | SAN DIEGO, CA 

Poster Information

Present a Poster and Save $50!

Cambridge Healthtech Institute encourages attendees to gain further exposure by presenting their work in the poster sessions. To secure a poster board and inclusion in the conference materials, your abstract must be submitted, approved and your registration paid in full by November 20, 2015.

Register online, or by phone, fax or mail.  Please indicate that you would like to present a poster.  Once your registration has been fully processed, we will send an email with a unique link and instructions for submitting your abstract using our online abstract submission tool.  Please see below for more information.

Reasons you should present your research poster at this conference:

  • Your poster will be seen by our international delegation, representing leaders from top pharmaceutical, biotech, academic and government institutions
  • Receive $50 off your registration 
  • Your poster abstract will be published in our conference materials 
  • Automatically entered into poster competition


  • You must select ONE track for your poster.  (Your poster selection must be concurrent with your registration selection, but it does not have to be the same.)
  • Your poster will hang only for the duration of your selected track.
  • Late posters will only be accepted if space allows. Late posters will not be included in conference materials. 

Note: Posters should be portrait orientation, with maximum dimensions of
36 inches wide (3 feet) x 48 inches high (4 feet).

* CHI reserves the right to publish your poster title and abstract in various marketing materials and products.

Click here for poster instructions and guidelines.

Poster inquiries: jring@healthtech.com

Confirmed Research Posters Include:

A High-Throughput Purification Platform for Generation of a Comprehensive Human Protein Library

A Platform for Antibody Expression Optimization: Miniaturized Transient Transfection of Expi293 and ExpiCHO cells, and Antibody Purification

Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates

Assisted Design of Antibody and Protein Therapeutics (ADAPT) ? Recent advances in the antibody affinity maturation platform

Automating mAb Workflows: Combining Tandem and Multi-D Purifications

Challenges Related to the Expression and Solubilization of Membrane-Associated Proteins

Characterization of Human Hepatic Lysosomes

Characterization of Protein Aggregates and Sub-visible Particles in Therapeutic Protein Formulations using ImageStreamx Imaging Flow Cytometry

Continuous Intensified Lyophilisation

Direct IHC by Using PolyHRP Labeled Trastuzumab (Herceptin) - A Potential New Companion Diagnostic Test for Herceptin Treatment

Discovery and Characterization of Therapeutic Antibodies for an Engineered Cell-Free Expression System

DoE Using Definitive Screening Design for Antibody Formulation

Efficient Elimination of Carcinoma Cells Expressing the Tumor Exclusive Target CLDN6 with a Bispecific Antibody

Employing Split-GFP and Droplet Microfluidics for the Selection of High-Producing CHO Cells

Engineer Deimmunized Lysostaphin Variants to Combat Lethal MRSA Infections

Engineering the CHO Cell

Engineering Thermostable Enzymes using Cell-Free Protein Synthesis at Elevated Temperatures

Genetic Expression of New Insulin Analogue

Improved Vaccine Formulation: A platform for RVF Clone 13 stability enhancement

Intranasal Delivery of Leptin N-Terminal Conjugates with Pluronic P85 for Treatment of Obesity

Isolation of Novel Escherichia coli Mutant for the Enhanced Production of Therapeutic Proteins via the SRP-Dependent Secretion Pathway

Morphology of Alpha-1 Proteinase Inhibitor Aggregates Monitored Using Hydrogen Deuterium Exchange and Covalent Labeling Mass Spectrometry

Next-generation DNA Sequencing As A Tool for Discovering Single-Domain Antibodies with Novel Phenotypes

Novel Affibody-Auristatin E Conjugate with Potent and Selective Activity Against HER2-Positive Cancer Cells

Novel Chloroquinoline Derivatives Incorporating Biologically Active Benzenesulfonamide Moiety: Synthesis, Cytotoxic Activity and Molecular Docking

Predicting Vial-to-Vial Variation in Maximum Temperature and Drying Time Within a Lyophilized Product Batch During Primary Drying

Production and scale-up of Amblyomin-X, an antitumor recombinant protein

Quantitative Subcellular Fractionation of CHO Cells

Rapid Fine Conformational Epitope Mapping Using Comprehensive Mutagenesis and Deep Sequencing

Sitagliptin-AntiCD4 Mab Conjugated T Cell Targeting Therapy for the Effective Treatment of Type I Diabetes

Structurally Motivated Approach to Design Bispecific Antibodies with Improved Developability

The 2.56 structure of human Jag 1 bound to the fab fragment of an antagonistic antibody reveals the molecular basis of anti-Jag1 antagonism and selectivity.

The NIH Protein Capture Reagent Initiative (PCRI): generation and validation of monospecific mouse monoclonal antibodies against all human transcription factors.

Thermally Responsive TRAIL Receptor Agonist Fusions Are Potent Cancer Therapeutics